AGAlain Michel Gardier

Alain Michel Gardier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alain Michel Gardier has a total of 78 co-authors. Here are the top co-authors by number of shared publications:

  • Denis Joseph David

    Centre de recherche en Epidémiologie et Santé des Populations (CESP), UMR 1018, CESP‐Inserm, Team Moods, Faculté de Pharmacie, Bâtiment Henri Moissan Université Paris‐Saclay, UVSQ Orsay France

    14 shared publications
  • Jean-Philippe Guilloux

    Faculté de Pharmacie Université Paris‐Saclay, UVSQ, Centre de Recherche en Epidémiologie et Santé Des Populations (CESP) Orsay France

    5 shared publications
  • René Hen

    Columbia University

    5 shared publications
  • Indira Mendez-David

    Équipe Moods, INSERM 1018, CESP (centre de recherche en épidémiologie et santé des population), Faculté de Médecine Université Paris‐Saclay Kremlin‐Bicêtre France

    4 shared publications
  • Bruno P. Guiard

    Univ Paris-Sud EA 3544, Faculté de Pharmacie, 5, rue JB Clément, Châtenay-Malabry Cedex F-92296, France

    3 shared publications
  • Indira Mendez-David

    Universite Paris-Saclay, Faculte de Pharmacie, CESP-Inserm, Chatenay Malabry, 92290, France

    3 shared publications

Latest Publications

  • Cortical and raphe GABAA, AMPA receptors and glial GLT-1 glutamate transporter contribute to the sustained antidepressant activity of ketamine

    by Thu Ha Pham, Céline Defaix, Thi Mai Loan Nguyen, Indira Mendez-David, Laurent Tritschler, Denis J. David, Alain M. Gardier


  • Open Access

    Cortical and raphe GABA A , AMPA receptors and glial GLT-1 glutamate transporter contribute to the sustained antidepressant activity of ketamine

    by Thu Ha Pham, Céline Defaix, Thi Mai Loan Nguyen, Indira Mendez-David, Laurent Tritschler, Denis J David, Alain M. Gardier

    At sub-anaesthetic doses, ketamine, a non competitive N-methyl-d-aspartate (NMDA) receptor antagonist, has demonstrated remarkable and rapid antidepressant (AD) efficacy in patients with treatment-resistant depression (TRD). However, its mechanism of action of ketamine is not fully understood. Since comorbid depression and anxiety disorders often occur, GABAergic/inhibitory and glutamatergic/excitatory drug treatments may be co-administered in these patients. Information regarding this combination is critical to establish efficacy or treatment restrictions to maximize translation from animal models to TRD patients, effectiveness and safety. To assess the specific role of excitatory/inhibitory neurotransmission in the medial prefrontal cortex-raphe nuclei (mPFC-DRN) circuit in the sustained antidepressant-like activity (AD) of ketamine (at t24h post dose), AMPA-R antagonist (intra-DRN) and GABA A -R agonist (intra-mPFC) were co-administered with ketamine (intra-mPFC). Twenty-four hours later, responses in the forced swim test (FST) and neurochemical consequences on extracellular mPFC glutamate, GABA and 5-HT levels were measured in BALB/cJ mice. Intra-DRN NBQX prevented the sustained AD-like activity of ketamine evidenced by decreases in FST swimming duration and blunted cortical 5-HT ext and Glu ext. Intra-mPFC muscimol blocked ketamine AD-like activity and its effects on cortical 5-HT ext . Moreover, a selective glutamate transporter GLT-1 inhibitor, dihydrokainic acid (DHK) locally perfused into the mPFC produced an AD-like activity at t24h associated with robust increases in mPFC 5-HT ext , Glu ext and GABA ext . Thus, the sustained AD-like activity of ketamine is triggered by AMPA-R activation in the DRN and 5-HT - glutamate release in the mPFC, but limited by GABA A -R activation - GABA release in the mPFC. The local blockade of GLT-1 in the mPFC also mimics the rapid responses of ketamine, thus highlighting the role of neuronal-glial adaptation in these effects. These results also suggests the need to test for the concomitant prescription of ketamine and BZD to see whether its sustained antidepressant activity is maintained in TRD patients.

  • Open Access

    Prophylactic efficacy of 5-HT 4 R agonists against stress

    by Briana K. Chen, Indira Mendez-David, Charlene Faye, Alain M. Gardier, Denis J. David, Christine A. Denny

    Enhancing stress resilience could protect against stress-induced psychiatric disorders in at-risk populations. We and others have previously reported that ( R , S )-ketamine acts as a resilience enhancing drug (e.g., prophylactic) against stress when administered 1 week before stress. While we have shown that the selective 5-hydroxytryptamine (5-HT) (serotonin) reuptake inhibitor (SSRI) fluoxetine (Flx) is ineffective as a prophylactic, it remains to be determined if other serotonergic drugs could be effective prophylactics. Here, we hypothesized that serotonin 4 receptor (5-HT 4 R) agonists could be prophylactic against fear, depressive-like, and/or anxiety-like behavior. We tested if three 5-HT 4 R agonists with varying affinity (e.g., partial or selective agonists) could protect against stress in two mouse strains by utilizing a chronic corticosterone (CORT) administration or a contextual fear conditioning (CFC) paradigm. Mice were administered RS-67,333, prucalopride, or PF-04995274 at varying doses and then 1 week later were subjected to chronic CORT or CFC. Chronic administration of RS-67,333, but not Flx was efficacious as a prophylactic against CORT in C57BL/6NTac mice. A single injection of RS-67,333 attenuated learned fear in male, but not female 129S6/SvEv mice. RS-67,333 was ineffective against stress-induced depressive-like behavior in the forced swim test (FST). A single injection of either prucalopride or PF-04995274 attenuated learned fear and decreased stress-induced depressive-like behavior. These data show that in addition to ( R , S )-ketamine, 5-HT 4 R agonists are also effective prophylactics against stress, suggesting that the 5-HT 4 R may be a novel target for prophylactic drug development.

  • Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine–Induced Sustained Antidepressant-like Effects

    by Thu Ha Pham, Céline Defaix, Xiaoming Xu, Shi-Xian Deng, Nicolas Fabresse, Jean-Claude Alvarez, Donald W. Landry, Rebecca A. Brachman, Christine A. Denny, Alain M. Gardier


  • Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB/cJ mice

    by T.H. Pham, I. Mendez-David, C. Defaix, B.P. Guiard, L. Tritschler, D.J. David, A.M. Gardier


  • Open Access

    Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease

    by Flavie Darcet, Alain M. Gardier, Raphael Gaillard, Denis J. David, Jean-Philippe Guilloux

    Major Depressive Disorder (MDD) is the most common psychiatric disease, affecting millions of people worldwide. In addition to the well-defined depressive symptoms, patients suffering from MDD consistently complain about cognitive disturbances, significantly exacerbating the burden of this illness. Among cognitive symptoms, impairments in attention, working memory, learning and memory or executive functions are often reported. However, available data about the heterogeneity of MDD patients and magnitude of cognitive symptoms through the different phases of MDD remain difficult to summarize. Thus, the first part of this review briefly overviewed clinical studies, focusing on the cognitive dysfunctions depending on the MDD type. As animal models are essential translational tools for underpinning the mechanisms of cognitive deficits in MDD, the second part of this review synthetized preclinical studies observing cognitive deficits in different rodent models of anxiety/depression. For each cognitive domain, we determined whether deficits could be shared across models. Particularly, we established whether specific stress-related procedures or unspecific criteria (such as species, sex or age) could segregate common cognitive alteration across models. Finally, the role of adult hippocampal neurogenesis in rodents in cognitive dysfunctions during MDD state was also discussed.


  • Nrf2-signaling and BDNF: A new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depression

    by Indira Mendez-David, Laurent Tritschler, Zeina El Ali, Marie-Hélène Damiens, Marc Pallardy, Denis J. David, Saadia Kerdine-Römer, Alain M. Gardier


  • 5-HT4 Receptor Subtype, β-Arrestin Level, and Rapid-Onset Effects of Antidepressant Drugs

    by Indira Mendez-David, Denis Joseph David, Jean-Philippe Guilloux, René Hen, Alain Michel Gardier


  • Open Access

    BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities

    by G Quesseveur, D J David, M C Gaillard, P Pla, M V Wu, H T Nguyen, V Nicolas, G Auregan, I David, A Dranovsky, et al.

    The therapeutic activity of selective serotonin (5-HT) reuptake inhibitors (SSRIs) relies on long-term adaptation at pre- and post-synaptic levels. The sustained administration of SSRIs increases the serotonergic neurotransmission in response to a functional desensitization of the inhibitory 5-HT1A autoreceptor in the dorsal raphe. At nerve terminal such as the hippocampus, the enhancement of 5-HT availability increases brain-derived neurotrophic factor (BDNF) synthesis and signaling, a major event in the stimulation of adult neurogenesis. In physiological conditions, BDNF would be expressed at functionally relevant levels in neurons. However, the recent observation that SSRIs upregulate BDNF mRNA in primary cultures of astrocytes strongly suggest that the therapeutic activity of antidepressant drugs might result from an increase in BDNF synthesis in this cell type. In this study, by overexpressing BDNF in astrocytes, we balanced the ratio between astrocytic and neuronal BDNF raising the possibility that such manipulation could positively reverberate on anxiolytic-/antidepressant-like activities in transfected mice. Our results indicate that BDNF overexpression in hippocampal astrocytes produced anxiolytic-/antidepressant-like activity in the novelty suppressed feeding in relation with the stimulation of hippocampal neurogenesis whereas it did not potentiate the effects of the SSRI fluoxetine on these parameters. Moreover, overexpressing BDNF revealed the anxiolytic-like activity of fluoxetine in the elevated plus maze while attenuating 5-HT neurotransmission in response to a blunted downregulation of the 5-HT1A autoreceptor. These results emphasize an original role of hippocampal astrocytes in the synthesis of BDNF, which can act through neurogenesis-dependent and -independent mechanisms to regulate different facets of anxiolytic-like responses.